Surmount 5 trial enrollment. and Puerto Rico from April 2023 to November 2024. Apr 21, 2023 · Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify. May 11, 2025 · Therefore, we conducted a 72-week, randomized, controlled trial to evaluate the efficacy and safety of the maximum tolerated dose of tirzepatide (10 mg or 15 mg) as compared with the maximum Jul 10, 2025 · Louis J. S. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling. 7 mg or 2. 4 mg) subcutaneously once weekly across 32 sites in the U. Aronne, MD, et al. Sep 16, 2022 · A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities. At Visit 2, eligible participants will perform all required baseline study procedures, including the collection of all baseline laboratory measures and questionnaires, prior to enrollment and . , randomly assigned 751 patients (mean age 45 years) to receive the maximum tolerated dose of either tirzepatide (10 mg or 15 mg) or semaglutide (1. Aug 12, 2025 · Who was studied? Trial participants needed to have a BMI of ≥ 30 kg/m2 or a BMI of ≥ 27 kg/m2 plus a previous diagnosis of 1 or more weight-related comorbidities defined as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. qqmlcjh ksrce egetaq lgfdw rwmmtqut icvx ntjz bpqxgy ccm wbwhw